argenx SE (NASDAQ:ARGX – Free Report) – Research analysts at William Blair increased their Q3 2024 earnings per share (EPS) estimates for argenx in a report issued on Monday, June 24th. William Blair analyst M. Minter now anticipates that the company will post earnings of ($0.47) per share for the quarter, up from their prior forecast of ($0.49). William Blair has a “Market Perform” rating on the stock. The consensus estimate for argenx’s current full-year earnings is ($2.89) per share. William Blair also issued estimates for argenx’s Q4 2024 earnings at ($0.46) EPS and FY2024 earnings at ($2.09) EPS.
argenx (NASDAQ:ARGX – Get Free Report) last issued its earnings results on Monday, May 13th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.33). argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. The company had revenue of $412.51 million during the quarter, compared to analyst estimates of $404.03 million. During the same quarter in the previous year, the firm earned ($0.52) earnings per share.
Get Our Latest Stock Report on ARGX
argenx Stock Performance
Shares of ARGX stock opened at $445.88 on Thursday. The business has a 50 day moving average of $379.85 and a two-hundred day moving average of $386.89. argenx has a 52 week low of $327.73 and a 52 week high of $550.76.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of ARGX. DekaBank Deutsche Girozentrale increased its stake in shares of argenx by 1.5% in the first quarter. DekaBank Deutsche Girozentrale now owns 8,445 shares of the company’s stock worth $3,320,000 after acquiring an additional 128 shares during the last quarter. Cetera Advisors LLC acquired a new position in shares of argenx in the first quarter worth $419,000. Wahed Invest LLC increased its stake in shares of argenx by 43.5% in the first quarter. Wahed Invest LLC now owns 656 shares of the company’s stock worth $258,000 after acquiring an additional 199 shares during the last quarter. Dynasty Wealth Management LLC acquired a new position in shares of argenx in the first quarter worth $213,000. Finally, Iron Triangle Partners LP acquired a new position in shares of argenx in the first quarter worth $17,717,000. Institutional investors own 60.32% of the company’s stock.
About argenx
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
See Also
- Five stocks we like better than argenx
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Why Paychex Stock’s Dip is the Best Opportunity in Today’s Cycle
- How to Invest in Biotech Stocks
- Any Pullback in Tech May Signal a Rotation into These 3 Sectors
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Stocks to Watch: Oracle, Casey’s, FedEx Signal Big Gains
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.